[CAS NO. 2136633-23-1] Disitamab vedotin
PRODUCTS SPECIFICATIONS [2136633-23-1]
DESCRIPTION [2136633-23-1]
Overview
| MDL | - |
|---|---|
| Molecular Weight | - |
| Molecular Formula | - |
| SMILES | [Disitamab vedotin] |
Summary
Disitamab vedotin (RC48) is an antibody-drug conjugate (ADC) comprising a monoclonal antibody against human epidermal growth factor receptor 2 (HER2) conjugated via a cleavable linker to the cytotoxic agent Monomethyl auristatin E (MMAE). Disitamab vedotin enhances antitumor immunity [1] .
IC50 & Target
|
HER2 |
In Vitro
The antibody part was a humanized monoclonal antibody targeting HER2, the small molecule toxin was monomethyl auristatin E (MMAE), a synthetic antineoplastic agent. A protease cleavable linker covalently attached MMAE to the antibody [2] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date | Phase |
|---|---|---|---|---|
| NCT05241899 | The First Affiliated Hospital of Zhengzhou University |
Gastric Cancer
|
May 7, 2022 | Phase 2 |
| NCT04311034 | RemeGen Co., Ltd. |
Non Small Cell Lung Cancer
|
September 26, 2018 | Phase 1|Phase 2 |
Appearance
Solid
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
References
- [1] Deeks ED. Disitamab Vedotin: First Approval. Drugs. 2021;81(16):1929-1935.
- [2] Jiang J, et al. Preclinical safety profile of disitamab vedotin：a novel anti-HER2 antibody conjugated with MMAE. Toxicol Lett. 2020;324:30-37.
- [3] Huang L, Wang R, Xie K, et al. A HER2 target antibody drug conjugate combined with anti-PD-(L)1 treatment eliminates hHER2+ tumors in hPD-1 transgenic mouse model and contributes immune memory formation. Breast Cancer Res Treat. 2022;191(1):51-61.
